Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients
Diabetes Mellitus, Type 2

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2
Eligibility Criteria
Inclusion criteria: Male and female patients with a diagnosis of Type 2 diabetes treated only with diet and exercise (drug naïve) or with one or two oral hypoglycemic agents (as single treatment or in combination) other than rosiglitazone or pioglitazone -treatment. Antidiabetic therapy has to be stable for at least 10 weeks prior to screening. Diagnosis of Type 2 diabetes with duration of at least 3 months Glycosylated haemoglobin A1 (HbA1c) of: 7.5-10.0% at screening for drug naïve patients (no wash-out needed) 7.0-9.0% at screening for patients treated with only one oral antidiabetic agent (wash-out required) 6.5-8.0% at screening for patients treated with two oral antidiabetic agents (wash-out required) HbA1c of 7.5%-10.0% at Visit 3 (beginning of the 2-week placebo run-in period). Age >=21 and <=75 years. BMI (Body Mass Index) >=25.0 and <=40 kg/m2. Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and local legislation Exclusion criteria: Clinically relevant cardiovascular disease (e.g., myocardial infarction, stroke or transient ischemic attack within six months before enrollment) Impaired hepatic function defined by serum levels of either alanine aminotransferase, aspartate aminotransferase or alkaline phosphatase above 3-fold upper limit of normal Renal insufficiency or impaired renal function defined by serum creatinine above upper limit of normal at screening Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or clinically relevant neurologic disorders (including cerebrovascular but with the exception of polyneuropathy) that would interfere with participation in the trial Chronic or clinically relevant acute infections (e.g., Human immunodeficiency virus, Hepatitis) History of relevant allergy/hypersensitivity that would interfere with trial participation (including allergy to investigational product or its excipients) Treatment with rosiglitazone or pioglitazone within 6 months prior to screening Treatment with insulin within 3 months prior to screening Alcohol or drug abuse within the last 3 months that would interfere with trial participation) Participation in another trial with an investigational drug within two months prior to administration or during the trial Fasting plasma glucose >240 mg/dl (= 13.3 mmol/L) at Visit 2, 3 or 4 any visit and confirmed by a second measurement (not on the same day) Pre-menopausal women (last menstruation <=1 year prior to signing informed consent) who: are not surgically sterile, or are nursing or pregnant; or are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial. Acceptable methods of birth control include transdermal patch, intra-uterine devices, oral, implantable or injectable contraceptives and vasectomised partner. No exception will be made. Intolerance of metformin
Sites / Locations
- 1218.5.10020 Boehringer Ingelheim Investigational Site
- 1218.5.10001 Boehringer Ingelheim Investigational Site
- 1218.5.10007 Boehringer Ingelheim Investigational Site
- 1218.5.10041 Boehringer Ingelheim Investigational Site
- 1218.5.10018 Boehringer Ingelheim Investigational Site
- 1218.5.10016 Boehringer Ingelheim Investigational Site
- 1218.5.10003 Boehringer Ingelheim Investigational Site
- 1218.5.10011 Boehringer Ingelheim Investigational Site
- 1218.5.10012 Boehringer Ingelheim Investigational Site
- 1218.5.10017 Boehringer Ingelheim Investigational Site
- 1218.5.10008 Boehringer Ingelheim Investigational Site
- 1218.5.10024 Boehringer Ingelheim Investigational Site
- 1218.5.10039 Boehringer Ingelheim Investigational Site
- 1218.5.10032 Boehringer Ingelheim Investigational Site
- 1218.5.10025 Boehringer Ingelheim Investigational Site
- 1218.5.10034 Boehringer Ingelheim Investigational Site
- 1218.5.10009 Boehringer Ingelheim Investigational Site
- 1218.5.10042 Boehringer Ingelheim Investigational Site
- 1218.5.10029 Boehringer Ingelheim Investigational Site
- 1218.5.10004 Boehringer Ingelheim Investigational Site
- 1218.5.10026 Boehringer Ingelheim Investigational Site
- 1218.5.10035 Boehringer Ingelheim Investigational Site
- 1218.5.10023 Boehringer Ingelheim Investigational Site
- 1218.5.10030 Boehringer Ingelheim Investigational Site
- 1218.5.10044 Boehringer Ingelheim Investigational Site
- 1218.5.10033 Boehringer Ingelheim Investigational Site
- 1218.5.10038 Boehringer Ingelheim Investigational Site
- 1218.5.10006 Boehringer Ingelheim Investigational Site
- 1218.5.10040 Boehringer Ingelheim Investigational Site
- 1218.5.10036 Boehringer Ingelheim Investigational Site
- 1218.5.10021 Boehringer Ingelheim Investigational Site
- 1218.5.10027 Boehringer Ingelheim Investigational Site
- 1218.5.10022 Boehringer Ingelheim Investigational Site
- 1218.5.10014 Boehringer Ingelheim Investigational Site
- 1218.5.61001 Boehringer Ingelheim Investigational Site
- 1218.5.61005 Boehringer Ingelheim Investigational Site
- 1218.5.61006 Boehringer Ingelheim Investigational Site
- 1218.5.61007 Boehringer Ingelheim Investigational Site
- 1218.5.61004 Boehringer Ingelheim Investigational Site
- 1218.5.61002 Boehringer Ingelheim Investigational Site
- 1218.5.11011 Boehringer Ingelheim Investigational Site
- 1218.5.11016 Boehringer Ingelheim Investigational Site
- 1218.5.11003 Boehringer Ingelheim Investigational Site
- 1218.5.11004 Boehringer Ingelheim Investigational Site
- 1218.5.11013 Boehringer Ingelheim Investigational Site
- 1218.5.11015 Boehringer Ingelheim Investigational Site
- 1218.5.11005 Boehringer Ingelheim Investigational Site
- 1218.5.11014 Boehringer Ingelheim Investigational Site
- 1218.5.11010 Boehringer Ingelheim Investigational Site
- 1218.5.11009 Boehringer Ingelheim Investigational Site
- 1218.5.11012 Boehringer Ingelheim Investigational Site
- 1218.5.11002 Boehringer Ingelheim Investigational Site
- 1218.5.11006 Boehringer Ingelheim Investigational Site
- 1218.5.11017 Boehringer Ingelheim Investigational Site
- 1218.5.11018 Boehringer Ingelheim Investigational Site
- 1218.5.42002 Boehringer Ingelheim Investigational Site
- 1218.5.42003 Boehringer Ingelheim Investigational Site
- 1218.5.42005 Boehringer Ingelheim Investigational Site
- 1218.5.42004 Boehringer Ingelheim Investigational Site
- 1218.5.42001 Boehringer Ingelheim Investigational Site
- 1218.5.70001 Boehringer Ingelheim Investigational Site
- 1218.5.70002 Boehringer Ingelheim Investigational Site
- 1218.5.70003 Boehringer Ingelheim Investigational Site
- 1218.5.70004 Boehringer Ingelheim Investigational Site
- 1218.5.70005 Boehringer Ingelheim Investigational Site
- 1218.5.38005 Boehringer Ingelheim Investigational Site
- 1218.5.38001 Boehringer Ingelheim Investigational Site
- 1218.5.38002 Boehringer Ingelheim Investigational Site
- 1218.5.38003 Boehringer Ingelheim Investigational Site
- 1218.5.38004 Boehringer Ingelheim Investigational Site
- 1218.5.38006 Boehringer Ingelheim Investigational Site
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Placebo Comparator
Experimental
Experimental
Experimental
Active Comparator
Placebo
BI 1356 0.5 mg
BI 1356 2.5 mg
BI 1356 5.0 mg
Metformin
Placebo tablets matching BI 1356
BI 1356 dose 1 once daily
BI 1356 dose 2 once daily
BI 1356 dose 3 once daily
Metformin